Clinical Relevance of Serum Vascular Endothelial Growth Factor and Interleukin-6 in Patients with Colorectal Cancer

Overview

Journal Saudi J Gastroenterol

Specialty Gastroenterology

Date 2011 May 7

PMID 21546718

Citations 24

Authors

Ayman Eldesoky

Ashraf Shouma

Yousef Mosaad

Amira Elhawary

Affiliations

Soon will be listed here.

Abstract

Background/aim: Some biological factors play a role in stimulation of malignant growth, metastasis and angiogenesis; however, their clinical relevance has not yet been well established for most of them. This work was aimed at studying the clinical relevance of serum vascular endothelial growth factor (VEGF) and interleukin-6 (IL-6), in patients with colorectal cancer (CRC).

Materials And Methods: Preoperative serum levels of VEGF and IL-6 were measured by enzyme-linked immuno-assay in 35 CRC patients and in 30 healthy controls.

Results: CRC patients with or without metastasis had significantly higher VEGF and IL-6 levels than healthy controls (all P < 0.001). Patients with advanced clinical stage had significantly higher levels of VEGF and IL-6 than those with early clinical stage (all P < 0.001). Also, patients with metastatic disease had significantly higher VEGF and IL-6 levels than those with localized disease (all P < 0.001). The diagnostic accuracy for invasiveness was 83% for VEGF (cut off value = 240 pg/ml) and 66% for IL-6 (cut off value = 6.7 pg/ml), with sensitivity 79% and 74% and specificity 68% and 59%, respectively.

Conclusion: In CRC patients, preoperative measurement of serum VEGF and Il-6 may prove useful non-invasive diagnostic indicators associated with advanced clinical stage and tumor metastasis that warrants further investigations.

Citing Articles

Chromosomal instability is associated with prognosis and efficacy of bevacizumab after resection of colorectal cancer liver metastasis.

Li W, Lan J, Zhou C, Yang R, Wang J, He J Ann Med. 2024; 56(1):2396559.

PMID: 39247989 PMC: 11385633. DOI: 10.1080/07853890.2024.2396559.

Interleukin-6-Positive Immune Cells as a Possible New Immunologic Marker Associated With the Colorectal Cancer Prognosis.

Gulubova M, Chonov D, Aleksandrova E, Ivanova K, Ignatova M, Vlaykova T Appl Immunohistochem Mol Morphol. 2024; 32(5):233-243.

PMID: 38712586 PMC: 11073565. DOI: 10.1097/PAI.0000000000001198.

Association between IL-6 and prognosis of gastric cancer: a retrospective study.

Liang P, Zhang Y, Jiang T, Jin T, Chen Z, Li Z Therap Adv Gastroenterol. 2023; 16:17562848231211543.

PMID: 38026103 PMC: 10657517. DOI: 10.1177/17562848231211543.

Dual effects of radiotherapy on tumor microenvironment and its contribution towards the development of resistance to immunotherapy in gastrointestinal and thoracic cancers.

Zhao D, Mo Y, Neganova M, Aleksandrova Y, Tse E, Chubarev V Front Cell Dev Biol. 2023; 11:1266537.

PMID: 37849740 PMC: 10577389. DOI: 10.3389/fcell.2023.1266537.

Immune Checkpoint Inhibitors, Small-Molecule Immunotherapies and the Emerging Role of Neutrophil Extracellular Traps in Therapeutic Strategies for Head and Neck Cancer.

OMeara C, Jafri Z, Khachigian L Int J Mol Sci. 2023; 24(14).

PMID: 37511453 PMC: 10380483. DOI: 10.3390/ijms241411695.

References

Pedersen B . The anti-inflammatory effect of exercise: its role in diabetes and cardiovascular disease control. Essays Biochem. 2006; 42:105-17. DOI: 10.1042/bse0420105. View

Pokorny R, Hunt L, Galandiuk S . What's new with tumor markers for colorectal cancer?. Dig Surg. 2000; 17(3):209-15. DOI: 10.1159/000018853. View

Street M, Miraki-Moud F, Sanderson I, Savage M, Giovannelli G, Bernasconi S . Interleukin-1beta (IL-1beta) and IL-6 modulate insulin-like growth factor-binding protein (IGFBP) secretion in colon cancer epithelial (Caco-2) cells. J Endocrinol. 2003; 179(3):405-15. DOI: 10.1677/joe.0.1790405. View

Fantini M, Pallone F . Cytokines: from gut inflammation to colorectal cancer. Curr Drug Targets. 2008; 9(5):375-80. DOI: 10.2174/138945008784221206. View

Bottomley M, WEBB N, Watson C, Holt L, Bukhari M, Denton J . Placenta growth factor (PlGF) induces vascular endothelial growth factor (VEGF) secretion from mononuclear cells and is co-expressed with VEGF in synovial fluid. Clin Exp Immunol. 1999; 119(1):182-8. PMC: 1905543. DOI: 10.1046/j.1365-2249.2000.01097.x. View

Miyata Y, Kanda S, Ohba K, Nomata K, Hayashida Y, Eguchi J . Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D. Clin Cancer Res. 2006; 12(3 Pt 1):800-6. DOI: 10.1158/1078-0432.CCR-05-1284. View

Yamamoto T, Kimura T, Ueta E, Tatemoto Y, Osaki T . Characteristic cytokine generation patterns in cancer cells and infiltrating lymphocytes in oral squamous cell carcinomas and the influence of chemoradiation combined with immunotherapy on these patterns. Oncology. 2003; 64(4):407-15. DOI: 10.1159/000070300. View

Ueno T, Toi M, Saji H, Muta M, Bando H, Kuroi K . Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer. Clin Cancer Res. 2000; 6(8):3282-9. View

Dranoff G . Cytokines in cancer pathogenesis and cancer therapy. Nat Rev Cancer. 2004; 4(1):11-22. DOI: 10.1038/nrc1252. View

10.

Crawford N, Colliver D, Galandiuk S . Tumor markers and colorectal cancer: utility in management. J Surg Oncol. 2004; 84(4):239-48. DOI: 10.1002/jso.10325. View

11.

Salgado R, Junius S, Benoy I, van Dam P, Vermeulen P, Van Marck E . Circulating interleukin-6 predicts survival in patients with metastatic breast cancer. Int J Cancer. 2002; 103(5):642-6. DOI: 10.1002/ijc.10833. View

12.

Jelkmann W . Pitfalls in the measurement of circulating vascular endothelial growth factor. Clin Chem. 2001; 47(4):617-23. View

13.

Willheim M, Thien R, Schrattbauer K, Bajna E, Holub M, Gruber R . Regulatory effects of 1alpha,25-dihydroxyvitamin D3 on the cytokine production of human peripheral blood lymphocytes. J Clin Endocrinol Metab. 1999; 84(10):3739-44. DOI: 10.1210/jcem.84.10.6054. View

14.

Banks R, FORBES M, Kinsey S, Stanley A, Ingham E, Walters C . Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br J Cancer. 1998; 77(6):956-64. PMC: 2150108. DOI: 10.1038/bjc.1998.158. View

15.

Shirota K, Leduy L, Yuan S, Jothy S . Interleukin-6 and its receptor are expressed in human intestinal epithelial cells. Virchows Arch B Cell Pathol Incl Mol Pathol. 1990; 58(4):303-8. DOI: 10.1007/BF02890085. View

16.

Greene F . TNM staging for malignancies of the digestive tract: 2003 changes and beyond. Semin Surg Oncol. 2003; 21(1):23-9. DOI: 10.1002/ssu.10018. View

17.

Hirano T . Interleukin 6 and its receptor: ten years later. Int Rev Immunol. 1998; 16(3-4):249-84. DOI: 10.3109/08830189809042997. View

18.

Ueda T, Shimada E, Urakawa T . Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol. 1994; 29(4):423-9. DOI: 10.1007/BF02361238. View

19.

Kinoshita T, Ito H, Miki C . Serum interleukin-6 level reflects the tumor proliferative activity in patients with colorectal carcinoma. Cancer. 1999; 85(12):2526-31. DOI: 10.1002/(sici)1097-0142(19990615)85:12<2526::aid-cncr6>3.0.co;2-3. View

20.

Dittadi R, Meo S, Fabris F, Gasparini G, Contri D, Medici M . Validation of blood collection procedures for the determination of circulating vascular endothelial growth factor (VEGF) in different blood compartments. Int J Biol Markers. 2001; 16(2):87-96. View